Denali therapeutics inc. DNLI.US Overview
DNLI AI Analysis & Strategy
Browsing restrictions can be lifted for a fee.
DNLI Current Performance
-3.54%
Denali therapeutics inc.
-1.83%
Avg of Sector
-0.40%
S&P500
DNLI Key Information
DNLI Revenue by Segments
Browsing restrictions can be lifted for a fee.
DNLI Net Income
Browsing restrictions can be lifted for a fee.
DNLI Cash Flow
Browsing restrictions can be lifted for a fee.
DNLI Profit Margin
Browsing restrictions can be lifted for a fee.
DNLI PE Ratio River
Browsing restrictions can be lifted for a fee.
DNLI Financial Forecast
Browsing restrictions can be lifted for a fee.
DNLI Earnings Table
Unit : USD
| QTR | Non-GAAP EPS | EPS YoY | EPS Surprise % | Sales | Sales YoY | Sales Surprise % | NPM |
|---|---|---|---|---|---|---|---|
| Current | |||||||
| 2024Q4 | |||||||
| 2024Q3 | |||||||
| 2024Q2 | |||||||
| 2024Q1 |
DNLI Profile
Denali Therapeutics Inc., a biopharmaceutical company, discovers and develops therapeutic candidates for neurodegenerative diseases in the United States. It offers leucine-rich repeat kinase 2 (LRRK2) inhibitor product candidate, including BIIB122/DNL151, a small molecule inhibitor, which is in phase I and phase Ib clinical trials for the treatment of Parkinson's disease. The company also develops DNL310 that is in Phase I/II clinical trials for the treatment of hunter syndrome; DNL343, which is in phase 1 clinical trial the treatment of amyotrophic lateral sclerosis (ALS); AR443820/DNL788 completed a phase I clinical trial for the treatment of ALS, multiple sclerosis (MS), and Alzheimer's disease; and SAR443122/DNL758, which is in phase II clinical trial for the treatment of cutaneous lupus erythematosus. It has collaboration agreement with Takeda Pharmaceutical Company, Genentech, Inc., Sanofi, F-star Gamma Limited, F-star Biotechnologische Forschungs-Und Entwicklungsges M.B.H, F-star Biotechnology Limited, SIRION Biotech GmbH, Genzyme Corporation, Harvard University, the Michael J. Fox Foundation, and Centogene; and a research and option agreement with Secarna Pharmaceuticals GmbH & Co. KG. to develop antisense therapies in the field of neurodegenerative diseases. The company was formerly known as SPR Pharma Inc. and changed its name to Denali Therapeutics Inc. in March 2015. Denali Therapeutics Inc. was incorporated in 2013 and is headquartered in South San Francisco, California.
Price of DNLI
DNLI FAQ
When is DNLI's latest earnings report released?
The most recent financial report for Denali therapeutics inc. (DNLI) covers the period of 2025Q1 and was published on 2025/03/31. This report is prepared according to IFRS/US GAAP standards and includes key financial indicators—Revenue, Profitability, Cash Flow, and Capital Structure. This information is essential for investors evaluating DNLI's short-term business performance and financial health. For the latest updates on DNLI's earnings releases, visit this page regularly.
How much debt does DNLI have?
As of the end of the reporting period, Denali therapeutics inc. (DNLI) had total debt of 48.63M, with a debt ratio of 0.04. Long-term debt comprises a higher/lower proportion. The level of financial leverage directly impacts the company's capital structure and interest coverage. If debt is high, pay attention to interest expenses and refinancing risks. Conversely, a low-leverage structure indicates greater risk tolerance but potentially less growth flexibility.
How much cash does DNLI have?
At the end of the period, Denali therapeutics inc. (DNLI) held Total Cash and Cash Equivalents of 56.95M, accounting for 0.04 of total assets. Both current and quick ratios indicate robust short-term debt repayment ability. High cash reserves typically mean the company has strong liquidity, supporting operational needs, expansion investments, or shareholder returns.
Is DNLI's EPS continuing to grow?
According to the past four quarterly reports, Denali therapeutics inc. (DNLI)'s earnings per share (EPS) shows a declining trend, with the latest EPS at -0.78. If EPS continues to rise due to revenue growth and cost optimization, it can support P/E valuation recovery and attract long-term investors.
What is the FCF of DNLI?
Denali therapeutics inc. (DNLI)'s Free Cash Flow (FCF) for the period is -136.55M, calculated as Operating Cash Flow minus Capital Expenditures, representing a fall of 17.95% compared with the previous period. Positive FCF growth provides stable funding for dividends, debt repayment, or strategic acquisitions, and is an important measure of true profitability and shareholder return potential.
What are the PEG ratio and PE ratio of DNLI?
The latest valuation data shows Denali therapeutics inc. (DNLI) has a Price-To-Earnings (PE) ratio of -4.47 and a Price/Earnings-To-Growth (PEG) ratio of -0.27. A PEG below 1 usually suggests the market is underestimating growth potential, while a PEG above 1 indicates high growth expectations are already priced in. Investors should conduct a comprehensive valuation by considering historical growth, market forecasts, and industry cycles.